Mesenkia Attracts Almi Invest's Backing to Combat Aggressive Brain Tumors
Deal News | Jun 03, 2025 | ALMI Invest Mitt AB
Almi Invest Mitt AB has invested 2.5 million kronor in Mesenkia Therapeutics AB, a life science company based in Uppsala, Sweden. Mesenkia is dedicated to developing an innovative treatment for glioblastoma, one of the most aggressive and lethal brain tumors, for which there is currently no effective treatment. This investment forms part of a larger funding round totaling 5.6 million kronor and includes participation from UU Invest and other stakeholders. The aim is to advance Mesenkia's research and development efforts towards providing a viable medical solution for glioblastoma patients.
Sectors
- Life Sciences
- Venture Capital
Geography
- Sweden – The investment and company activities are taking place in Sweden, specifically involving Almi Invest Mitt AB and Mesenkia Therapeutics AB based in Uppsala.
Industry
- Life Sciences – The article is centered around Mesenkia Therapeutics AB, which operates in the life sciences industry, focusing on developing pharmaceutical solutions for aggressive brain tumors.
- Venture Capital – The article involves investments from a venture capital firm, Almi Invest, in a biotech startup, which is indicative of activities within the venture capital sector.
Financials
- 2,500,000 kronor – The amount invested by Almi Invest Mitt AB in Mesenkia Therapeutics AB.
- 5,600,000 kronor – The total amount of the financing round in which Almi Invest and others are participating.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Almi Invest Mitt AB | Investor | Company | A Swedish venture capital firm that is investing in Mesenkia Therapeutics AB. |
| Mesenkia Therapeutics AB | Target Company | Company | An Uppsala-based life science company developing treatments for glioblastoma. |
| UU Invest | Investor | Company | Another investor participating in the same financing round as Almi Invest Mitt AB. |